XML 85 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (USD $)
In Thousands, except Share data, unless otherwise specified
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Balance at Jun. 30, 2009 $ 23,541 $ 18 $ 248,500 $ (227,048) $ 2,071
Balance, shares at Jun. 30, 2009   18,293,961      
Comprehensive income:          
Net income 8,753     8,753  
Foreign currency translation adjustments (1,548)       (1,548)
Net unrealized gain on marketable securities (2)       (2)
Total comprehensive income 7,203        
Exercise of warrants 484   484    
Exercise of warrants, Shares   100,000      
Exercise of stock options 318 1 317    
Exercise of stock options,Shares   110,000      
Issuance of fully vested shares 110   110    
Issuance of fully vested shares, shares   27,431      
Stock-based compensation 1,385   1,385    
Balance at Jun. 30, 2010 33,041 19 250,796 (218,295) 521
Balance, shares at Jun. 30, 2010   18,531,392      
Comprehensive income:          
Net income (8,628) [1]     (8,628)  
Foreign currency translation adjustments 919       919
Net unrealized gain on marketable securities (11)       (11)
Total comprehensive income (7,720)        
Issuance of stock, net of issue costs (in shares)   2,210,000      
Issuance of stock, net of issue costs 10,043 2 10,041    
Exercise of stock options 17   17    
Exercise of stock options,Shares   7,250      
Stock-based compensation 2,052   2,052    
Balance at Jun. 30, 2011 37,433 21 262,906 (226,923) 1,429
Balance, shares at Jun. 30, 2011 20,748,642 20,748,642      
Comprehensive income:          
Net income (24,835) [2],[3]     (24,835)  
Foreign currency translation adjustments (492)       (492)
Net unrealized gain on marketable securities 5       5
Total comprehensive income (25,322)        
Exercise of stock options 114   114    
Exercise of stock options,Shares   53,950      
Stock-based compensation 1,411   1,411    
Balance at Jun. 30, 2012 $ 13,636 $ 21 $ 264,431 $ (251,758) $ 942
Balance, shares at Jun. 30, 2012 20,802,592 20,802,592      
[1] Results for the fourth quarter of fiscal 2011 included $3.3 million of revenue related to a material modification of the Pfizer collaborative research and license agreement in June 2011 (see Note 3).
[2] Results for the first quarter of fiscal 2012 included $1.1 million of revenue related to the termination of a field-of-use license by Intrinsiq (see Note 3)
[3] Results for the second quarter of fiscal 2012 included a $14.8 million impairment write-down of finite-lived intangible assets (see Note 4).